And, of course let’s not forget that forward sales curve up toward $100M in gross revenue.
I can well imagine that 9,128 cxbladder sales in FY14 is entirely achievable, the user programmes alone will contribute much of that.
Attachment 4744
Printable View
And, of course let’s not forget that forward sales curve up toward $100M in gross revenue.
I can well imagine that 9,128 cxbladder sales in FY14 is entirely achievable, the user programmes alone will contribute much of that.
Attachment 4744
Wouldn't be surprised if a lot of fund managers are looking at this opportunity as a five year entry point.
now I just have to decide when to buy...
yup definitely a buyers market out there, 50 cent just got filled, wouldn't be surprised if it got to 45 cents today
Wow, I smell a great chance to top up here! SP for these guys often doesn't make sense, we get told that the company is on track for making 100m in a few years, that everything is as expected, no negative announcements and the SP drops by 15%?? I smell opportunity...
Hopefully we will see one or two NZ DHB's sign up in a big way here, their results would be analysed closely by the American LUG's I suspect.
I agree with others how the ppt looked pretty unprofessional, like it was done in the plane by David on his way back from America! To me thats still a sign of someone more interested in driving their product sales in real terms instead of selling it to investors.
Very happy to be holding (and topping up) still :-)
Wow.... I think it is crazy to be 'topping up' - it is in the middle of a strong breakout to the down side. All the 'topping up' may push it back up to the new resistance line of the breakout, but that will more than likely just be a bounce before continuing on its new trend (down!).
The time to top up is when it bottoms out, reverses, and heads back up again.
There must be a peace pipe I'm not smoking or something - a 100 million in 5 years with no, as of yet, sales data...?? I guess if the CEO says so then it must be true....
It seems there may have been a bit of unrealistic expectation regarding what might have been announced at the agm.
As has been mentioned on this thread previously, getting GP's and urologists to change their current practices and to adopt cxbladder will take some time, probably longer than expected. They are a conservative bunch and rightly so when it comes to adopting new technologies. They will need to be certain that cxbladder can do what the company says it can do and provide a positve step change to justify adopting a new diagnostic tool.
Hence the comments at the meeting regarding signifigant pre-purchase dissonance regarding uptake by clinicians and physicians. But the reassuring thing for me was the setting up of the user program so clinicans can test drive the test and see for themselves how good it is. The user program seems to be a success as evidenced by the blinded trials carried out by the DHB's in NZ. Further user programs are being carried out and this is where the sales will flow from, especially in the US. As a result of carrying out the user programs I would expect sales to really start to pick up next year after a lot of these programs are completed. I would'nt be expecting some great sales numbers before then.
The good thing about this is that it does act as a barrier to any future competition. As David Darling mentioned, competition will come but there is a relatively long lead in time for anyone else to get a product to market, as we are seeing.
David also made the comment that one of the large shareholders had made a couple of visits to the lab in Hershey to check things out for themselves and they seemed to be happy with what they saw. Although the shareprice has come back since the meeting, I would be more concerned if some of the larger shareholders were selling out at this point. So far we don't see that and the turnover is on fairly low volumes.
Over the next few months I think we will see some more deals with DHB's and the signing up of some of the urological organisations in the US. That's what will most likely give the shareprice some support.
All in all I thought it was a good meeting and although progress is slower that some might like, we are definitely heading in the right direction.
The problem of course blakecb is knowing where the bottom is, where do you catch the falling knife?
For me, after looking at all the other options, I know CxBladder is a superior product that is cheaper and more accurate than its competition. They appear to have the right people in place to drive a superior product to market. They have lined up everything they need to sell it and we are simply in a waiting game for this to happen. While there may be political risks involved with getting the product to market, I can't see a situation where a health board is going to say "No, we don't want to use this better product for less money" in a time of economic belt tightening.
I believe in a few years this will be a very valuable share. So snapping up as many of them now at what will be a huge discount makes a lot of sense to me. I don't trade on technicals though, rather on management/company performance plus product and market potential.
Agree with you Sparky.
Also, with Blakecb's quote ... "There must be a peace pipe I'm not smoking or something - a 100 million in 5 years with no, as of yet, sales data...?? I guess if the CEO says so then it must be true....", I wonder if he/she has analysed the TA or FA of XRO?
exactly right turmeric IMO, I'm thinking that fact (no mention of any sales traction out of the AGM) is the catalyst for this selloff, pure and simple.Quote:
To extend that point a bit further - XRO's SP didn't really take off until they developed a history of growth in paying customers - I supsect the same will be the case for PEB.
I have added today though, as this was also the case a week ago, and the fundamentals can be bought ~15% cheaper
topped up 51 cents, might go lower, might not. Everything seems to be lining up in terms of product, sales, markets etc. now hold and wait for news on sales. Riskvs reward is strongly in favour of reward.
I guess my comment was a bit hostile, so apologies on my part.
You may be surprised to hear Sparky that I've read every bit of bladder cancer news and article posted on this thread. While I've haven't done my own external research, the information and articles I've seen have provided me with a very good idea of what the company offers and the massive international potential of it for the diagnosis of bladder cancer. I did all of that before I initially bought into the company. I sold, as per a previous post, because it seemed clear to me that what has just happened would happen. I want a bit more certainty that the stock is on an upward trajectory before hanging on for the ride. I will undoubtedly get back into this stock, before it takes off to the moon, if I see it turn around and begin uptrending.
@ blobbles, there is no reason to try and catch the falling knife at all - there will be buy signals at the right time. You may miss the very bottom, but you wont buy and find it the hard way.
As for the comment on XRO...I like the software a lot, but would never buy into that company for a plethora of reasons I won't go into, no matter what TA or FA told me.
Blakecb ......you got into trouble eh .....big trouble I reckon
Good apology to the masses though .....unnecessary though
Suppose you are allowed to continue commenting now ....but please don't upset the apple cart
Thanks for another lesson Turmeric. I totally acknowledge that when it comes to XRO - you are the guru as I notice you sold at the absolute SP apex - about a month ago (& congrats on that!!). However, what has changed in the FA or TA that has made the SP plummet 15% in the last month or so?
I suspect PEB's current SP wouldn't be where it currently is if they had an entrepreneur running things - as opposed to more cautious Dr's/scientists etc.
To be clear - I am very happy with what PEB management is doing and how they are managing things.